Cancer Research Institute, Guangdong Medical University, Dongguan, 523808, China.
Pathology Department, Guangdong Medical University, Dongguan, 523808, China.
Med Oncol. 2022 Jul 14;39(10):148. doi: 10.1007/s12032-022-01727-7.
Gene editing interference technology has been flourishing for more than 30 years. It has always been a common means to interfere with the expression of particular genes. Today it has shown a broad application prospect in clinical treatment, especially in adenocarcinoma treatment. In just a few years, the CRISPRi technology has attracted much z attention with its precise targeting and convenient operability significantly promoted the transformation from bench to bedside, and won the Nobel Prize in Chemistry 2020. In recent years, the importance of non-coding RNA has led LncRNA research to the center. At the same time, it also recalls the surprises obtained in laboratory and clinic research by RNAi technologies such as microRNA, siRNA, and shRNA at the beginning of the century. Therefore, this article focuses on CRISPRi, RNAi, and LncRNA to review their gene interference mechanisms currently expected to be translational research. Their applications and differences in adenocarcinoma research will also be described powerfully. It will provide a helpful reference for scientists to understand better and apply several RNA interference technologies.
基因编辑干扰技术已经蓬勃发展了 30 多年。它一直是干扰特定基因表达的常用手段。如今，它在临床治疗中显示出了广阔的应用前景，尤其是在腺癌治疗中。在短短几年内，CRISPRi 技术以其精确的靶向性和便捷的可操作性引起了广泛关注，极大地推动了从实验室到临床的转化，并获得了 2020 年诺贝尔化学奖。近年来，非编码 RNA 的重要性使得 LncRNA 研究成为焦点。同时，这也唤起了本世纪初 microRNA、siRNA 和 shRNA 等 RNAi 技术在实验室和临床研究中获得的惊喜。因此，本文重点介绍了 CRISPRi、RNAi 和 LncRNA，以回顾它们目前有望转化研究的基因干扰机制。还将有力地描述它们在腺癌研究中的应用和差异。这将为科学家们更好地理解和应用几种 RNA 干扰技术提供有益的参考。
